3
Announcements
Trials
Browse
Landscape
Status
Active not recruiting
1
Sponsor Class
OTHER
1
Study Type
Observational
1
Interventional
1
Sponsor
Cancer Type
Breast
1
Conditions
Breast Neoplasms
12
Neoplasm Metastasis
2
Vulvar Neoplasms
1
Vaginal Neoplasms
1
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Urethral Neoplasms
1
Thyroid Neoplasms
1
Testicular Neoplasms
1
Small Cell Lung Carcinoma
1
Sarcoma
1
Salivary Gland Neoplasms
1
Prostatic Neoplasms
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Neoplasm, Residual
1
Mouth Neoplasms
1
Melanoma
1
Liver Neoplasms
1
Head and Neck Neoplasms
1
HER2-positive Gastric Cancer
1
HER2-positive Breast Cancer
1
HER2-positive Advanced Gastric Cancer
1
HER2 Overexpression
1
Gastrointestinal Stromal Tumors
1
Gastrointestinal Neoplasms
1
Gallbladder Neoplasms
1
Esophageal Neoplasms
1
Endometrial Neoplasms
1
Drug-Related Side Effects and Adverse Reactions
1
Interventions
Blood Specimen Collection
6
Liquid Biopsy
3
Chemotherapy, Adjuvant
2
trastuzumab deruxtecan
1
pegaspargase
1
Vincristine
1
Trastuzumab
1
Transplantation, Autologous
1
Prednisone
1
Neoadjuvant Therapy
1
Methotrexate
1
Mercaptopurine
1
Hematologic Tests
1
Drug Therapy
1
Doxorubicin
1
Daunorubicin
1
Cytoreduction Surgical Procedures
1
Cytarabine
1
Cyclophosphamide
1
Clonal Evolution
1
Anti-Inflammatory Agents, Non-Steroidal
1
Aminolevulinic Acid
1
Ado-Trastuzumab Emtansine
1
Adjuvants, Pharmaceutic
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Observational
×
Neoplasm, Residual
×
trastuzumab deruxtecan
×
Clear all
NCT06663787
2026-05-13
HER2 CR
Nagoya City University
Active not recruiting
50 enrolled